Cargando…

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy

Detalles Bibliográficos
Autores principales:	Ferraro, Francesca, Gruszczynska, Agata, Ruzinova, Marianna B., Miller, Christopher A., Percival, Mary Elizabeth, Uy, Geoffrey L., Pusic, Iskra, Jacoby, Meagan A., Christopher, Mathew J., Kim, Miriam Y., Westervelt, Peter, Cashen, Amanda F., Schroeder, Mark A., DiPersio, John F., Abboud, Camille N., Wartman, Lukas D., Gao, Feng, Link, Daniel C., Ley, Timothy J., Welch, John S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244807/ https://www.ncbi.nlm.nih.gov/pubmed/35236053 http://dx.doi.org/10.3324/haematol.2021.280153

Ejemplares similares

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
por: Barnell, Erica K., et al.
Publicado: (2021)

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
por: Uy, Geoffrey L., et al.
Publicado: (2016)

The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML
por: Wong, Terrence N., et al.
Publicado: (2014)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells
por: Wilson, Elisabeth R., et al.
Publicado: (2021)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
por: Slade, Michael, et al.
Publicado: (2016)

Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes
por: Ferraro, Francesca, et al.
Publicado: (2021)

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
por: Uy, G L, et al.
Publicado: (2017)

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
por: Wong, Terrence N., et al.
Publicado: (2018)

Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease
por: Abboud, Ramzi, et al.
Publicado: (2020)

Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice
por: Wartman, Lukas D., et al.
Publicado: (2012)

Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia
por: Petti, Allegra A., et al.
Publicado: (2022)

A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia
por: Lu, Charles, et al.
Publicado: (2016)

Mouse models of graft-versus-host disease: advances and limitations
por: Schroeder, Mark A., et al.
Publicado: (2011)

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
por: Fang, Y., et al.
Publicado: (2022)

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

Mobilized peripheral blood: an updated perspective
por: Karpova, Darja, et al.
Publicado: (2019)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
por: Crees, Zachary D., et al.
Publicado: (2023)

Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing
por: Hughes, Andrew E. O., et al.
Publicado: (2014)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019)

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide
por: Crees, Zachary D., et al.
Publicado: (2023)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
por: Wang, Yuxin, et al.
Publicado: (2022)

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment
por: Longmate, Whitney, et al.
Publicado: (2017)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
por: Stiff, Patrick J., et al.
Publicado: (2023)

Challenges in Conducting Studies in Chronic Graft-versus-Host Disease
por: Pusic, Iskra, et al.
Publicado: (2019)

Comparative use of CRISPR and RNAi to modulate integrin α3β1 in triple negative breast cancer cells reveals that some pro-invasive/pro-metastatic α3β1 functions are independent of global regulation of the transcriptome
por: Kenney, James, et al.
Publicado: (2021)

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
por: Mims, Alice, et al.
Publicado: (2023)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jdi4l2fr8qo3hsdi0v4lcbhfpb